Aniracetam

CAT: 0804-HY-10932-01Size: 500 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-10932-01Size:500 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropics effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevents the CO2-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders[1][2][3][4].

CAS Number

72432-10-1

Product Name Alternative

Ro 13-5057

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IGluR; nAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Aniracetam.html

Concentration

10mM

Purity

99.94

Solubility

DMSO : ≥ 100 mg/mL|H2O : 0.33 mg/mL (ultrasonic)

Smiles

O=C(N1CCCC1=O)C2=CC=C(OC)C=C2

Molecular Formula

C12H13NO3

Molecular Weight

219.24

Precautions

H302, H315, H319, H335

References & Citations

[1]Nakamura K, et al. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420 (1) :33-43.|[2]Vaglenova J, et al. Aniracetam reversed learning and memory deficits following prenatal ethanol exposure by modulating functions of synaptic AMPA receptors. Neuropsychopharmacology. 2008 Apr;33 (5) :1071-83. Epub 2007 Jul 4.|[3]Ito I, et al. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol. 1990 May;424:533-43.|[4]Cumin R, et al. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology (Berl) . 1982;78 (2) :104-11.|[5]Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev. 2002 Spring;8 (1) :70-89.|[6]Pizzi M, et al. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. J Neurochem. 1993 Aug;61 (2) :683-9.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

AMPA Receptor

Alternative Products

Catalog	Name
B1210-5000	Aniracetam

Aniracetam

Alternative Products

Popular Products